• Basecamp Research has raised $60 million in Series B funding and established a collaboration with the Broad Institute's David Liu lab to develop programmable genetic medicines.
• The London-based startup is leveraging its extensive biological interactions database to train AI models, distinguishing itself from traditional AI drug discovery approaches.
• The partnership aims to explore novel fusion proteins and large molecules, with potential applications in gene editing by studying bacterial-viral warfare mechanisms.